High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S)

Yoana Petrova, Hannah Mattan, Guat Ling Lee, Maksims Jevglevskis, Timothy Woodman, Matthew Lloyd

Research output: Contribution to conferencePoster

12 Downloads (Pure)

Abstract

α-Methylacyl-CoA racemase (AMACR; P504S) catalyzes a key step in the degradation of branched-chain fatty acids and is important for the pharmacological activation of Ibuprofen and related drugs. Both the concentration and activity of AMACR are increased in prostate and other cancer cells, and the enzyme is a recognized drug target. However, all of the reported inhibitors are acyl-CoA esters (which do not comply with Lipinski guidelines) or non-specific protein modifying agents.
Libraries of ~20,000 drug-like compounds were screened using a novel colorimetric assay; Incubation of R,S-2-3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA with active AMACR resulted in the elimination of the strongly yellow 2,4-dinitrophenoxide and allows continuous measurement of activity in a microtitre plate format. Inhibitors were identified by a reduction in the rate of reaction in the presence of the library compound vs. the control. A number of novel reversible inhibitors were identified and their potency determined using dose-response curves. The results demonstrate the utility of the assay for the discovery and characterization of AMACR inhibitors as anti-cancer agents.

This work was funded by Prostate Cancer UK (PG14-009), a Biochemical Society Summer Vacation Studentship Award, The Nuffield Foundation and MRC technology.
Original languageEnglish
Publication statusPublished - 21 Apr 2017
Event1st International Cancer Research @Bath symposium - University of Bath, Bath, UK United Kingdom
Duration: 20 Apr 201721 Apr 2017

Conference

Conference1st International Cancer Research @Bath symposium
CountryUK United Kingdom
CityBath
Period20/04/1721/04/17

Fingerprint

Libraries
Prostatic Neoplasms
Pharmaceutical Preparations
Acyl Coenzyme A
Ibuprofen
Coenzyme A
Esters
Fatty Acids
Pharmacology
Guidelines
Technology
Enzymes
alpha-methylacyl-CoA racemase
Neoplasms
Proteins

Cite this

Petrova, Y., Mattan, H., Lee, G. L., Jevglevskis, M., Woodman, T., & Lloyd, M. (2017). High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S). Poster session presented at 1st International Cancer Research @Bath symposium, Bath, UK United Kingdom.

High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S). / Petrova, Yoana; Mattan, Hannah; Lee, Guat Ling; Jevglevskis, Maksims; Woodman, Timothy; Lloyd, Matthew.

2017. Poster session presented at 1st International Cancer Research @Bath symposium, Bath, UK United Kingdom.

Research output: Contribution to conferencePoster

Petrova, Y, Mattan, H, Lee, GL, Jevglevskis, M, Woodman, T & Lloyd, M 2017, 'High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S)' 1st International Cancer Research @Bath symposium, Bath, UK United Kingdom, 20/04/17 - 21/04/17, .
Petrova Y, Mattan H, Lee GL, Jevglevskis M, Woodman T, Lloyd M. High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S). 2017. Poster session presented at 1st International Cancer Research @Bath symposium, Bath, UK United Kingdom.
Petrova, Yoana ; Mattan, Hannah ; Lee, Guat Ling ; Jevglevskis, Maksims ; Woodman, Timothy ; Lloyd, Matthew. / High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S). Poster session presented at 1st International Cancer Research @Bath symposium, Bath, UK United Kingdom.
@conference{3a4446cf13e848c199781f708b90610f,
title = "High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S)",
abstract = "α-Methylacyl-CoA racemase (AMACR; P504S) catalyzes a key step in the degradation of branched-chain fatty acids and is important for the pharmacological activation of Ibuprofen and related drugs. Both the concentration and activity of AMACR are increased in prostate and other cancer cells, and the enzyme is a recognized drug target. However, all of the reported inhibitors are acyl-CoA esters (which do not comply with Lipinski guidelines) or non-specific protein modifying agents.Libraries of ~20,000 drug-like compounds were screened using a novel colorimetric assay; Incubation of R,S-2-3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA with active AMACR resulted in the elimination of the strongly yellow 2,4-dinitrophenoxide and allows continuous measurement of activity in a microtitre plate format. Inhibitors were identified by a reduction in the rate of reaction in the presence of the library compound vs. the control. A number of novel reversible inhibitors were identified and their potency determined using dose-response curves. The results demonstrate the utility of the assay for the discovery and characterization of AMACR inhibitors as anti-cancer agents.This work was funded by Prostate Cancer UK (PG14-009), a Biochemical Society Summer Vacation Studentship Award, The Nuffield Foundation and MRC technology.",
author = "Yoana Petrova and Hannah Mattan and Lee, {Guat Ling} and Maksims Jevglevskis and Timothy Woodman and Matthew Lloyd",
year = "2017",
month = "4",
day = "21",
language = "English",
note = "1st International Cancer Research @Bath symposium ; Conference date: 20-04-2017 Through 21-04-2017",

}

TY - CONF

T1 - High-Throughput Screening to identify novel inhibitors of human α-methylacyl-CoA racemase 1A (AMACR; P504S)

AU - Petrova, Yoana

AU - Mattan, Hannah

AU - Lee, Guat Ling

AU - Jevglevskis, Maksims

AU - Woodman, Timothy

AU - Lloyd, Matthew

PY - 2017/4/21

Y1 - 2017/4/21

N2 - α-Methylacyl-CoA racemase (AMACR; P504S) catalyzes a key step in the degradation of branched-chain fatty acids and is important for the pharmacological activation of Ibuprofen and related drugs. Both the concentration and activity of AMACR are increased in prostate and other cancer cells, and the enzyme is a recognized drug target. However, all of the reported inhibitors are acyl-CoA esters (which do not comply with Lipinski guidelines) or non-specific protein modifying agents.Libraries of ~20,000 drug-like compounds were screened using a novel colorimetric assay; Incubation of R,S-2-3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA with active AMACR resulted in the elimination of the strongly yellow 2,4-dinitrophenoxide and allows continuous measurement of activity in a microtitre plate format. Inhibitors were identified by a reduction in the rate of reaction in the presence of the library compound vs. the control. A number of novel reversible inhibitors were identified and their potency determined using dose-response curves. The results demonstrate the utility of the assay for the discovery and characterization of AMACR inhibitors as anti-cancer agents.This work was funded by Prostate Cancer UK (PG14-009), a Biochemical Society Summer Vacation Studentship Award, The Nuffield Foundation and MRC technology.

AB - α-Methylacyl-CoA racemase (AMACR; P504S) catalyzes a key step in the degradation of branched-chain fatty acids and is important for the pharmacological activation of Ibuprofen and related drugs. Both the concentration and activity of AMACR are increased in prostate and other cancer cells, and the enzyme is a recognized drug target. However, all of the reported inhibitors are acyl-CoA esters (which do not comply with Lipinski guidelines) or non-specific protein modifying agents.Libraries of ~20,000 drug-like compounds were screened using a novel colorimetric assay; Incubation of R,S-2-3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA with active AMACR resulted in the elimination of the strongly yellow 2,4-dinitrophenoxide and allows continuous measurement of activity in a microtitre plate format. Inhibitors were identified by a reduction in the rate of reaction in the presence of the library compound vs. the control. A number of novel reversible inhibitors were identified and their potency determined using dose-response curves. The results demonstrate the utility of the assay for the discovery and characterization of AMACR inhibitors as anti-cancer agents.This work was funded by Prostate Cancer UK (PG14-009), a Biochemical Society Summer Vacation Studentship Award, The Nuffield Foundation and MRC technology.

M3 - Poster

ER -